Evaluation of an RBD-nucleocapsid fusion protein as a booster candidate for COVID-19 vaccine.

Publication date: Jul 19, 2024

Despite successful vaccines and updates, constant mutations of SARS-CoV-2 makes necessary the search for new vaccines. We generated a chimeric protein that comprises the receptor-binding domain from spike and the nucleocapsid antigens (SpiN) from SARS-CoV-2. Once SpiN elicits a protective immune response in rodents, here we show that convalescent and previously vaccinated individuals respond to SpiN. CD4 and CD8 T cells from these individuals produced greater amounts of IFN-γ when stimulated with SpiN, compared to SARS-CoV-2 antigens. Also, B cells from these individuals were able to secrete antibodies that recognize SpiN. When administered as a boost dose in mice previously immunized with CoronaVac, ChAdOx1-S or BNT162b2, SpiN was able to induce a greater or equivalent immune response to homologous prime/boost. Our data reveal the ability of SpiN to induce cellular and humoral responses in vaccinated human donors, rendering it a promising candidate.

Open Access PDF

Concepts	Keywords
Cd4	Health sciences
Nucleocapsid	Immunology
Rodents	Public health
Successful	Virology
Vaccines

Semantics

Type	Source	Name
disease	VO	COVID-19 vaccine
disease	IDO	immune response
disease	VO	vaccinated
disease	VO	dose
disease	VO	immunized
disease	VO	CoronaVac
disease	MESH	COVID 19
drug	DRUGBANK	Coenzyme M
disease	VO	vaccine
disease	MESH	pneumonia
disease	MESH	acute respiratory distress syndrome
disease	MESH	sepsis
disease	MESH	thrombocytosis
disease	MESH	death
disease	VO	manufacturing
disease	VO	time
disease	VO	immunization
disease	VO	Ad26.COV2.S
disease	VO	effectiveness
pathway	REACTOME	Immune System
disease	IDO	production
disease	VO	effective
disease	VO	population
drug	DRUGBANK	Aspartame
disease	VO	vaccination
disease	IDO	assay
disease	VO	frequency
disease	IDO	cell
drug	DRUGBANK	Proline
disease	VO	protocol
disease	VO	titer
disease	VO	efficient
drug	DRUGBANK	Spinosad
disease	MESH	cowpox
disease	MESH	smallpox
disease	IDO	history
disease	MESH	yellow fever
drug	DRUGBANK	N-acetylsulfanilyl chloride
disease	VO	vaccine candidate
disease	VO	regulatory agency
disease	VO	vaccine dose
disease	IDO	blood
disease	IDO	process
disease	VO	vaccine effectiveness
drug	DRUGBANK	(S)-Des-Me-Ampa
drug	DRUGBANK	Sulfasalazine
disease	VO	USA
disease	MESH	Morbidity
disease	VO	inactivated vaccine
disease	MESH	Infection
drug	DRUGBANK	Cefaclor
drug	DRUGBANK	Flunarizine
drug	DRUGBANK	Streptomycin
drug	DRUGBANK	Ammonium chloride
drug	DRUGBANK	Potassium
disease	VO	Bacteria
drug	DRUGBANK	Kanamycin
drug	DRUGBANK	Isopropyl beta-D-thiogalactopyranoside
drug	DRUGBANK	Histidine
drug	DRUGBANK	Urea
disease	VO	manufacturer
drug	DRUGBANK	Ribostamycin
drug	DRUGBANK	Immune Globulin Human
disease	VO	viability
disease	VO	dead
disease	VO	viable
drug	DRUGBANK	Resiquimod
drug	DRUGBANK	Carboxymethylcellulose

Original Article

(Visited 3 times, 1 visits today)